Compared with anti-PD-1 (nivolumab) treatment alone, the combination of anti-PD-1 and anti-CTLA4 (ipilimumab) treatment resulted in an ORR of 38% (vs. 25.6%), a median tumor lesion change from baseline of −30.0% (vs. +1.9%), and median overall survival of 15.3 months (vs. 9.9 months), at the best dose combination (Sharma et al., 2019). Here, CTLA4 is linked to neoplasm.